ADIAL PHARMACEUTICALS, INC. short interest in 2021
In 2021, ADIAL PHARMACEUTICALS, INC.'s disclosed short interest ran from 2.60% of shares outstanding on 15 Jan 2021 to 4.15% on 31 Dec 2021, a change of +1.55 percentage points. The year's high was 7.21% on 30 Jun 2021 and its low 2.43% on 29 Jan 2021, averaging 4.27% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.07 days on 15 Dec 2021. Full history: ADIAL PHARMACEUTICALS, INC..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2021 in figures
- Start of year
- 2.60% (15 Jan 2021)
- End of year
- 4.15% (31 Dec 2021)
- Change
- +1.55 pp
- High
- 7.21% (30 Jun 2021)
- Low
- 2.43% (29 Jan 2021)
- Average
- 4.27%
- Highest days to cover
- 7.07 (15 Dec 2021)
- SEC filings marked
- 4
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2021 | 2.60% | 1.00 | |
| 29 Jan 2021 | 2.43% | 1.00 | |
| 12 Feb 2021 | 3.30% | 1.00 | |
| 26 Feb 2021 | 3.56% | 1.00 | |
| 15 Mar 2021 | 3.85% | 1.46 | |
| 31 Mar 2021 | 3.64% | 1.74 | 10-K filed |
| 15 Apr 2021 | 4.24% | 4.79 | |
| 30 Apr 2021 | 3.83% | 4.71 | |
| 14 May 2021 | 3.67% | 5.01 | |
| 28 May 2021 | 4.09% | 5.87 | 10-Q filed |
| 15 Jun 2021 | 3.54% | 2.13 | |
| 30 Jun 2021 | 7.21% | 1.00 | |
| 15 Jul 2021 | 5.40% | 1.00 | |
| 30 Jul 2021 | 6.32% | 4.20 | |
| 13 Aug 2021 | 4.87% | 1.87 | 10-Q filed |
| 31 Aug 2021 | 4.38% | 1.07 | |
| 15 Sep 2021 | 4.25% | 2.59 | |
| 30 Sep 2021 | 4.69% | 1.91 | |
| 15 Oct 2021 | 4.85% | 4.09 | |
| 29 Oct 2021 | 4.31% | 2.56 | |
| 15 Nov 2021 | 4.79% | 3.39 | 10-Q filed |
| 30 Nov 2021 | 4.53% | 2.80 | |
| 15 Dec 2021 | 4.10% | 7.07 | |
| 31 Dec 2021 | 4.15% | 6.34 |
See also: ADIAL PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.